back
Get SIGNAL/NOISE in your inbox daily
Lila Sciences, a Cambridge-based AI-biotech startup, raised $235 million to achieve unicorn status at over $1 billion valuation, following a $200 million seed round. It develops a “scientific superintelligence” platform integrating AI and robotic labs for accelerated drug discovery and sustainable materials. This funding reflects booming investor interest in AI-driven life sciences innovation.
Recent Stories
Jan 19, 2026
App Store apps are exposing data from millions of users
An effort led by security research lab CovertLabs is actively uncovering troves of (mostly) AI-related apps that leak and expose user data.
Jan 19, 2026Stop ignoring AI risks in finance, MPs tell BoE and FCA
Treasury committee urges regulators and Treasury to take more ‘proactive’ approach
Jan 19, 2026OpenAI CFO Friar: 2026 is year for ‘practical adoption’ of AI
OpenAI CFO Sarah Friar said the company is focused on "practical adoption" in 2026, especially in health, science, and enterprise.